Rhythm Pharmaceuticals, Inc. remains a compelling rare-disease obesity platform, with a maintained Buy rating driven by progress in HO, PWS, and oral MC4R agonists. PWS Phase 2 data for IMCIVREE show ...
The last time I spoke about Rhythm Pharmaceuticals, Inc. (RYTM) it was in a Seeking Alpha article entitled "Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity Disorder." With respect to ...
A new study reveals that alpha brain waves help the brain decide what belongs to your body. Faster rhythms allow the brain to match sight and touch more precisely, strengthening the feeling that a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results